| Theme | IPMN/Pancreatic Cyst as an Increasing Common Disease -- Current Status and Issues | |
|---|---|---|
| Title | How Long Should Surveillance for IPMN be Continued? | |
| Publish Date | 2019/11 | |
| Author | Hiroki Oyama | Department of Gastroenterology, Graduate school of Medicine, The University of Tokyo |
| Author | Minoru Tada | Department of Gastroenterology, Graduate school of Medicine, The University of Tokyo |
| Author | Tsuyoshi Hamada | Department of Gastroenterology, Graduate school of Medicine, The University of Tokyo |
| Author | Yousuke Nakai | Department of Gastroenterology, Graduate school of Medicine, The University of Tokyo |
| Author | Kazuhiko Koike | Department of Gastroenterology, Graduate school of Medicine, The University of Tokyo |
| [ Summary ] | IPMN is known as a risk factor of pancreatic carcinoma, for which surveillance is recommended to detect pancreatic malignancy earlier. Using several imaging modalities is important for asymptomatic IPMN, but it can lead to an increase in medical costs. " High risk stigmata" and "Worrisome features" are criteria for the risk of IPMN‒derived carcinoma, but can't always be applied for concomitant pancreatic carcinoma. Recommended duration for surveillance differs by guidelines. Furthermore, the incidence of pancreatic carcinoma is not rare even after five years of surveillance. The criteria for duration and interval of surveillance based on clinical evidence are needed. From an economic viewpoint, a strategy for selecting the low risk group, as well as a high risk group, is also important. | |